Magadh Chronicle

DelveInsight’s, “Metastatic-Liver-Cancer Pipeline Insight, 2023” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the Metastatic-Liver-Cancer pipeline drug profiles, including Metastatic-Liver-Cancer clinical trials and nonclinical stage products. It also covers the Metastatic-Liver-Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Metastatic-Liver-Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic-Liver-Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic-Liver-Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Metastatic-Liver-Cancer Pipeline Report

• DelveInsight’s Metastatic-Liver-Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic-Liver-Cancer treatment.

• The leading Metastatic-Liver-Cancer Companies includes Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.

• Promising Metastatic-Liver-Cancer Pipeline Therapies includes Adecatumumab, FOLFOX 4, EMD 525797, AV-299, AZD2171, Talimogene Laherparepvec, Atezolizumab, STP705, and others.

• The Metastatic-Liver-Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Metastatic-Liver-Cancer R&D. The Metastatic-Liver-Cancer pipeline therapies under development are focused on novel approaches to treat/improve Metastatic-Liver-Cancer.

To explore more information on the latest breakthroughs in the Metastatic-Liver-Cancer Pipeline treatment landscape of the report, click here @ Metastatic-Liver-Cancer Pipeline Outlook

Metastatic-Liver-Cancer Overview

The liver is a common site for metastases from many cancer types. Cancers that spread to the liver most often are colorectal cancer as well as with breast, esophageal, stomach, pancreatic, lung, kidney and melanoma skin cancers. Cancers spread to the liver because the liver filters most of the blood from the rest of the body, and when cancer cells break away from a primary cancer, they often enter and travel through the bloodstream. Sometimes the discovery of metastatic liver cancer is the first indication that a person has cancer. Often, the first symptoms are vague. They include weight loss, poor appetite, and sometimes fever. Typically, the liver is enlarged and hard. It may feel tender and often lumpy. Occasionally, the spleen is enlarged.

Metastatic-Liver-Cancer Emerging Drugs Profile

exoASO STAT6: Codiak BioSciences

exoASO™-STAT6 is an exosome therapeutic candidate engineered using our engEx™ Platform to overexpress Codiak’s novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

STP 705: Sirnaomics

STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

ONCR 177: Oncorus

ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

For further information, refer to the detailed Metastatic-Liver-Cancer Unmet Needs, Metastatic-Liver-Cancer Market Drivers, and Market Barriers, click here for Metastatic-Liver-Cancer Ongoing Clinical Trial Analysis

Metastatic-Liver-Cancer Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Metastatic-Liver-Cancer. The companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.

Metastatic-Liver-Cancer Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request a sample and discover the recent advances in Metastatic-Liver-Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic-Liver-Cancer Treatment Landscape

Scope of the Metastatic-Liver-Cancer Pipeline Insight Report

• Coverage- Global
• Metastatic-Liver-CancerCompanies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Metastatic-Liver-Cancer Pipeline Therapies- Adecatumumab, FOLFOX 4, EMD 525797, AV-299, AZD2171, Talimogene Laherparepvec, Atezolizumab, STP705, and others
• Metastatic-Liver-Cancer Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Mantle Cell Lymphoma Market Drivers and Mantle Cell Lymphoma Market Barriers, click here @ Mantle Cell Lymphoma Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic-Liver-Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic-Liver-Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name :Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name :Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ONCR 177: Oncorus
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name :Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic-Liver-Cancer Key Companies
21. Metastatic-Liver-Cancer Key Products
22. Metastatic-Liver-Cancer- Unmet Needs
23. Metastatic-Liver-Cancer- Market Drivers and Barriers
24. Metastatic-Liver-Cancer- Future Perspectives and Conclusion
25. Metastatic-Liver-Cancer Analyst Views
26. Metastatic-Liver-Cancer Key Companies
27. Appendix

Got Queries? Find out the related information on Metastatic-Liver-Cancer Mergers and acquisitions, Metastatic-Liver-Cancer Licensing activities @ Metastatic-Liver-Cancer Emerging Drugs, and Recent Trends

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services